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2 
Abstract  1 
Dietary protein intake might be beneficial to physical function (PF) in elderly. We examined the 2 
cross-sectional and prospective associations of protein intake g/kg body weight (BW), fat mass 3 
(FM) and lean mass (LM) with PF in 554 women aged 65·3-71·6 year belonging to OSTPRE-FPS 4 
study. Participants filled a questionnaire on lifestyle factors and 3-day food record in 2002. Body 5 
composition was measured by dual-energy X-ray absorptiometry and PF measures were performed 6 
at baseline and at 3 year follow-up. Sarcopenia was defined using European Working Group on 7 
Sarcopenia in Older People criteria. At the baseline women with higher protein intake (≥1·2 g/ kg 8 
BW) had better performance in hand grip strength/body mass (GS/BM) (P=0·001), knee 9 
extension/BM (P=0·003), one leg stance (P=0·047), chair rise (P=0·043), squat (P=0·019), squat to 10 
the ground (P=0·001), faster walking speed 10 m (P=0·005) and higher short physical performance 11 
battery score (P=0·004), than those with moderate and lower intakes (0·81-1·19 and ≤ 0·8 g/ kg 12 
BW, respectively). In follow-up results, higher protein intake was associated with less decline in 13 
GS/BM, one leg stance and tandem walk 6 m over 3years. Overall, results were no longer 14 
significant after controlling for FM. Associations were detected between protein intake and PF in 15 
non-sarcopenic women, but not in sarcopenic women except for change of GS (P=0·037). Further, 16 
FM but not LM was negatively associated with PF measures (P<0∙050). This study suggests that 17 
higher protein intake and lower FM might be positively associated with PF in elderly women.   18 
3 
Introduction 19 
The etiology of sarcopenia is multifactorial. The European Working Group on Sarcopenia in Older 20 
People (EWGSOP) has provided a working definition of sarcopenia (1,2). They proposed that 21 
sarcopenia is diagnosed using the criteria of low lean mass (LM) and low physical performance 22 
either low muscle strength (MS) and/or low physical function (PF) in elderly (1,2). It is known that 23 
decline in MS and PF are important contributing factors of the quality of life and increase the risk of 24 
frailty, fracture and falls in older individuals (2-4). Although the etiology of the decline in physical 25 
performance is not fully understood, poor nutrition may contribute to its development and 26 
progression (5). Therefore, measurement of MS and PF as indicators of physical performance status 27 
as well as nutritional status gained considerable attention in the past years (6). 28 
Indeed, new evidence shows that adequate dietary protein is beneficial to support good health, 29 
promote recovery from illness, and maintain LM in older adults (7-11). It also has positive association 30 
with MS and PF (12-15). However, the adequacy of current recommended dietary allowance (RDA) 31 
(16) for protein 0·8 g/ kg per body weight (BW) has been questioned recently regarding that it might 32 
not be enough to maintain the LM and prevent functional decline among elderly (5,17,18). To this end, 33 
recent reviews and consensus statements have suggested that a protein intake between 1·0 and 1·5 34 
g/kg/day may confer health benefits beyond those afforded by simply meeting the minimum (5,19). It 35 
might be inappropriate also to generalize the protein intake requirements based on healthy young 36 
men to older adults (18). PROT-AGE Study Group recommendations for dietary protein intake in 37 
healthy older adults is an average in the range of 1·0 to 1·2 g/kg BW (11). Further, Nordic nutrition 38 
recommendation 2012 (NNR) for elderly also suggested protein intake in the range of 1·1-1·3 g/kg 39 
BW (1·2 g/kg BW for planning purposes on population level) (20-22). 40 
Ageing is accompanied with changes in body composition with a gradual increase in the proportion 41 
of fat mass (FM) and decline in LM (23). LM is the main reservoir of protein in human body and it 42 
has a significant role in movement and posture, regulation of metabolism, and storage of energy and 43 
nitrogen (24). Previous studies supported the correlation between decreased LM and impaired 44 
physical performance (25). In a study by Pedrero et al. (26) elderly men and women with sarcopenic 45 
obesity showed lower physical fitness levels compared to non-sarcopenic subjects (27). Notably, 46 
older individuals have an attenuated muscle protein synthetic response after the ingestion of dietary 47 
protein and amino acids. This resistance to the usually anabolic effect of protein on myofibrillar 48 
protein synthesis (MPS) may partially contribute to the age-related decline in LM (28). Because of 49 
metabolic changes associated with ageing, elderly persons may produce less LM than younger 50 
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people from the same amount of ingested protein (29). It is recommended, therefore, that in cases of 51 
acute illness or psychological stress or sarcopenia higher protein intake is required (30). 52 
Primary aim of present study was to evaluate the differences in MS and PF in elderly women with 53 
higher protein intake than current daily allowance as compared to those with lower intake at the 54 
baseline and over 3-year follow-up. We hypothesized that a positive association of protein intake 55 
with PF measures is more pronounced in non-sarcopenic women as compared to those with 56 
diagnosed sarcopenia based on EWGSOP criteria (2). Further, the associations of total body FM and 57 
LM with PF and MS measures were examined at the baseline and at 3 year of follow-up. 58 
Subjects and methods 59 
Study design and participants 60 
Data of the present study were collected from the Osteoporosis Risk Factor and Prevention study 61 
(OSTPRE-FPS), which was a 3-year intervention to investigate the effect of calcium and vitamin D 62 
supplementation on the incidence of falls and fractures among elderly women (31). Inclusion criteria 63 
were being older than 65 year of age by the end of November 2002, residing in Kuopio region and 64 
no previous participation in OSTPRE bone densitometry sample (31). Supplementation group 65 
received daily cholecalciferol 800 IU and calcium 1000 mg for 3 years while the control group 66 
received neither supplementation nor placebo with the aim to study the effects of vitamin D and 67 
calcium supplementation on bone mineral density. In total 750 women were randomly taken into 68 
this subsample for participating in detailed examinations including measurement of body 69 
composition, physical performance tests and food records (32). Out of those, 554 women returned 70 
valid food record and had valid body composition and physical performance measurements for both 71 
at the baseline and at the 3-year follow-up. All clinical measurements were performed in Kuopio 72 
Musculoskeletal Research Unit of the Clinical research center of the University of Kuopio. All 73 
participants provided written permission for participation. The study was approved in October 2001 74 
by the ethical committee of Kuopio University Hospital. The study was registered in Clinical 75 
trials.gov by the identification NCT00592917. 76 
Body composition measurements 77 
Height and weight of participants were measured in light indoor clothing without shoes, body mass 78 
index (BMI) was calculated by weight (kg) divided in height squared meter. FM and LM were 79 
measured by dual-energy X-ray absorptiometry (DXA) by specially trained nurses. The DXA 80 
measurements carried out using the same Lunar Prodigy adhering to the imaging and analysis 81 
protocols provided by the manufacturer (Lunar Co., Madison, WI, USA) (32). DXA is currently a 82 
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common tool suitable for estimation of body composition in terms of evaluating the ratio between 83 
fat, muscle, and bone in different parts of the body (33). DXA also has been showed to be superior to 84 
bioimpedance for estimation of the body composition (34). 85 
Physical performance measurements 86 
Physical performance measures were assessed by trained nurses at the baseline and at year 3, 87 
consisting of three main domains: (1) MS: hand grip strength (GS) (kPa), number of chair rises in 88 
30 seconds, ability to squat and ability to squat to the ground and knee extension (kPa). (2) Mobility 89 
test: walking speed (WS) 10 m (m/s) and tandem walk for 6 m (m/s); and (3) Balance ability: 90 
standing with closed eyes for 10 seconds and one leg stance performance for 30 seconds. GS was 91 
measured in a controlled sitting position with a pneumatic hand-held dynamometer (Martin 92 
Vigorimeter, Germany) by calculating the mean of three successive measurements from the 93 
dominant hand. To standardize, GS and knee extension were further expressed as a ratio to body 94 
mass (BM) (FM+LM) which have been suggested to be better predictor of GS and knee extension 95 
alone (35,36). The chair rise test was conducted if participant was able to stand at least once without 96 
using arms from a straight-backed, non-padded, armless chair. Any measurement errors were 97 
excluded from the statistical analysis (37). The follow-up variable of knee extension was excluded 98 
from analysis due to unexpected increase in measured extension force and/or possible data entry 99 
errors. Further, based on EWGSOP definition short physical performance battery (SPPB) score was 100 
calculated using three individual measures of physical performance including WS 10 m (m/s), chair 101 
rises in 30 seconds and one leg stance performance categorized in quartiles (38). Each quartile was 102 
scored on scale of 1-4 points with the total score ranging to 12; higher scores of SPPB indicates 103 
better performance. Further, absolute changes in PF and MS measures were calculated by 104 
subtracting the baseline measures from those measured at year 3. The magnitude of meaningful 105 
changes in physical performance measures as well as SPPB have been evaluated previously, and 106 
these measures are consistently used as preferred indicators of physical performance in older adults 107 
(2,38,39). 108 
Diagnosis of sarcopenia 109 
Relative skeletal muscle index (RSMI) was calculated as the sum of the nonfat, nonbone skeletal 110 
muscle in arms and legs divided by the square of height (m2). Women were subdivided into 111 
quartiles according to their RSMI values: (1) 5·3–6·3 kg/m2, (2) 6·3–6·7 kg/m2, (3) 6·7–7·2 kg/m2 112 
and (4) 7·2–9·.3 kg/m2. Baumgartner et al.(23) reported that the sarcopenia cutoff point was 5·45 113 
kg/m2, which was calculated as two standard deviations below the mean in young reference 114 
population. However, in our study there were only six women whose RSMI was less than 5·45 115 
6 
kg/m2. Accordingly, we decided to use the lowest quartile below 6·3 kg/m2 as cutoff in the present 116 
study (37) . The study population was divided into quartiles also for their GS: (1) < 22·3 kPa, (2) 117 
22·3–25·7 kPa, (3) 25·7–28·7 kPa and (4) 28·7–40 kPa. Physical performance test was assessed by 118 
measuring WS by a 10-meter-WS test in a controlled situation and the WS was divided into 119 
quartiles: (1) < 0·51 m/s, (2) 1·42–1·63 m/s, (3) 1·64–1·85 m/s and (4) >1·85 m/s. The women who 120 
were not able to walk were allocated into the group of the lowest quartile. A woman was classified 121 
as sarcopenic if she belonged to the lowest quartile of RSMI and the lowest quartile of either GS or 122 
WS or both. A non-sarcopenic woman did not belong to the lowest quartile of any measurement 123 
(RSMI, GS or WS), whereas pre-sarcopenic women were in the lowest quartile of RSMI but not in 124 
the lowest quartile of any other outcome measure. Non-classified women belonged to the lowest 125 
quartile of either GS or WS or both, but not to that of RSMI. 126 
Dietary intakes 127 
Dietary intake was collected by using 3-day food record at the baseline. A questionnaire and 128 
instructions were sent to the participants beforehand, and they were returned on the visiting day. 129 
Participants were advised to fill the questionnaire for 3 consecutive days, including 2 days during 130 
the week and one day in the weekend (Saturday or Sunday). Participants were instructed to write 131 
down everything they ate and drank and to evaluate the amount of food consumed using household 132 
measures. In case of uncertainties in the food record, a nutritionist called the participant for 133 
additional information (40). To assess the underreporting the ratio of energy intake to estimated basal 134 
metabolic rate was calculated based on BW according to equations given by Department of Health 135 
in the UK(41). The ratio of energy intake to basal metabolic rate cutoff value for under-reporting was 136 
chosen to be 1·49, as derived from Goldberg et al.(42) and Black (43) and none of the participants was 137 
excluded from the analyses. Nutritional intake from food was calculated using Nutrica program 138 
(version 2·5, Finnish social insurance institute, Turku, Finland). Collected data provided 139 
calculations of animal and plant sources of protein in addition to total protein intake. 140 
Potential confounders 141 
All lifestyle related information was gathered by the self-administered questionnaire. The 142 
questionnaire included questions on age, hormone therapy use (never used or used), time since 143 
menopause (year), smoking status (never, former and current), self-reported calcium and vitamin D 144 
supplementation and alcohol consumption (portions/week). Total physical activity was based on 145 
self-reported amounts of sports, recreation and miscellaneous activities, including walking, jogging, 146 
skiing, cycling, swimming, aerobic exercise, ball sports and other more strenuous activities. Women 147 
were asked how many days they performed each activity per month. The sum of each activity days 148 
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during all twelve months were summed and divided by 12 in order to obtain the mean activity level 149 
per month. Furthermore, the mean activity level was multiplied by self-reported of strenuousness of 150 
the exercise (the scale was 1 (low) to 4 (strenuous)) (37). 151 
Statistical analysis 152 
Protein intake was reported as crude protein intake per BW (g/kg BW). Protein intake was 153 
categorized based on three different nutrition recommendations, RDA (16) (≤ 0·8 g/ kg BW), PROT-154 
AGE Study Group recommendation (11) (0·81-1·19· g/ kg BW), and NNR recommendation (≥ 1·2 155 
g/ kg BW) (20). For the purpose of this study, these three categories were referred to as lower, 156 
moderate and higher intake, respectively. Continuous variables were compared across the protein 157 
intake categories using ANOVA and ANCOVA and categorical variables using chi-square tests.  158 
Mean and SD of PF and MS measures at the baseline and absolute changes in them were tested in 159 
the ANCOVA across the categories of protein intake. Multiple linear regression or logistic 160 
regression models were used to calculate (β) and 95% CI of PF and MS measures at the baseline 161 
and changes in them across categories of protein intake. Tests for a linear trend across categories of 162 
protein intake were conducted by using the median value in each category as a continuous variable 163 
in the linear and logistic regression models. Pair wise comparisons of the group means were 164 
performed with Tukey’s post hoc test. Linear and logistic regression analyses evaluated the 165 
association of FM and LM with PF and MS measures at the baseline and over 3-year follow-up. We 166 
examined further the association of protein intake g/kg BW with PF measures at baseline and over 167 
3-year follow-up according to sarcopenia status. To achieve balanced numbers of participants in the 168 
stratified analysis and to evaluate our secondary hypothesis, women were classified as sarcopenic if 169 
they belonged to pre-sarcopenia, sarcopenia and severe sarcopenia (lowest quartile of RSMI) and 170 
non-sarcopenic group was compiled from normal and non-classified groups (normal RSMI).  171 
We initially assessed known covariates of frailty, including age, total energy intake, smoking status, 172 
alcohol consumption (portions/week), physical activity (hours/ week), hormone therapy use, 173 
osteoporosis and self-reported history of medical conditions (fall in last 12 months, depression, 174 
diabetes mellitus, hypertension and rheumatoid arthritis) and also for baseline height, FM and LM. 175 
Further, covariates were selected based on their multicollinearity and their predictive values alone, 176 
which lead to selection of the following models. Model 1 presents the unadjusted results controlling 177 
only for age and energy intake. Model 2 was adjusted for variables in model 1 plus smoking status, 178 
alcohol consumption, physical activity, hormone therapy use, osteoporosis, LM and height. Model 3 179 
was adjusted for variables in model 2 but LM was replaced by FM. Longitudinal analyses were 180 
adjusted for vitamin D and calcium supplementation (study group) to control for plausible vitamin 181 
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D effect on physical performance; as well as PF and MS baseline measures to account for 182 
differential subsequent changes in physical performance depending on the initial physical 183 
performance measures. Comparing model 2 and 3 provided opportunity to evaluate if LM and FM 184 
differently associate with PFs and MS as suggested by previous studies (4,44,45).  185 
All statistical analysis were executed using SPSS software version 21 for Windows (IBM Corp., 186 
Armonk, NY). Result was considered significant if a P value was < 0·05. 187 
Results  188 
The participants were 65·3- 71·6 years old (mean (±SD) age was 68 ± 1·9), and mean energy intake 189 
was 6560 ± 1556 kJ/d (Table 1). Total protein intake was 68·2 g/d which constituted to 17% of total 190 
energy intake and corresponded to 0·96 g/ kg BW. The minimum protein intake reported was 0.24 191 
g/kg BW and the maximum 2.25 g/kg BW. Also, 30% of women had protein intake ≤ 0·8 g/ kg 192 
BW, 48 % were in the moderate range of 0·8-1·19 g/ kg BW, while 22% consumed protein ≥ 1·2 g/ 193 
kg BW. Higher protein intake was significantly associated with higher energy intake and lower 194 
carbohydrate intake as % of energy, but higher carbohydrate intake as g/d.  195 
In total, 8 % of women had osteoporosis, 42% had hypertension, 3 % had diabetes, 6% had 196 
rheumatoid arthritis, 3 % had depression, 12% had hip arthrosis, 28 % had knee arthrosis and 21∙8 197 
% reported fall accident in past 12 months. However, no significant associations between reported 198 
diseases and protein intake g/kg BW were observed. Mean duration of hormone therapy was 11 199 
years and time passed after menopause was 18 years. Women with higher protein intake reported 200 
more frequent use of hormone therapy, weighed less and had lower BMI as compared to moderate 201 
and lower intake. Among body composition measurements FM, LM and LM index were 202 
significantly lower in higher protein intake. Women in higher protein intake had significantly higher 203 
RSMI than the lower protein intake group. 204 
In the Table 2 differences of baseline characteristics between non-sarcopenic and sarcopenic 205 
participants are presented. Sarcopenic group (n = 127) had significantly lower mean weight (-206 
13∙2%), BMI (-12∙7%), FM (-16∙0%) and LM (-12∙0%) as compared to non-sarcopenic group (n 207 
=369). Average protein intake was similar in sarcopenic and non-sarcopenic group, 17·6 ± 2·9 % 208 
and 17·9 ± 3·1 % of energy, respectively. 209 
Significant differences in physical performance measures between women with higher protein 210 
intake and those with lower protein intake at the baseline and over 3-year follow-up were detected 211 
(Table 3). At the baseline after adjustment for selected factors previously described as associated 212 
with physical performance (model 2) those with higher protein intake as compared to those with 213 
9 
moderate and lower intake had greater GS/BM (P = 0·001), knee extension/BM (P = 0·003), longer 214 
one leg stance performance (P= 0·047), better chair rise performance (P = 0·043), faster WS 10m 215 
pace (P = 0∙005), squat completion (P = 0·019) and squat to the ground completion (P = 0·001), 216 
and higher SPPB score ( P = 0·004). Overall results were no longer significant after controlling for 217 
FM (model 3). Results for the prospective analysis showed that those with higher protein intake had 218 
less decline in GS/BM (P = 0·027), one leg stance performance duration (P = 0·024) and had 219 
increased tandem walk speed (P = 0·024), which were no longer significant after controlling for 220 
FM.  221 
In linear regression analyses with physical performance measures and SPPB as the dependent 222 
measures, results from models including energy-adjusted fat intake (g/d), or energy-adjusted 223 
carbohydrate intake (g/d) as determinant instead of protein showed no significant contribution for 224 
fat (g/d) and carbohydrate (g/d) (data not sown). 225 
Further, we examined the association of protein intake with physical performance measures 226 
according to sarcopenia status (Table 4). Results of model 2 showed that among non-sarcopenic 227 
women protein intake was positively associated with GS/BM (β = 0·35 and P= 0·001), knee 228 
extension/BM (β = 0·25 and P =0·008), one leg stance performance (β= 0·26 and P= 0·001), chair 229 
rises (β = 0·15 and P= 0·039), WS 10 m (β = 0·30 and P< 0·001), ability to squat (β = 0·18 and P= 230 
0·003), squat to the ground (β = 0·29 and P= 0·001) and also with SPPB score (β = 0·32 and P< 231 
0·001) at the baseline. However, significant associations were lost after controlling for FM. Results 232 
of the prospective analysis indicated that higher protein intake in non-sarcopenic women was in 233 
positive relationship with changes of one leg stance performance (β = 0·14 and P= 0·037) and 234 
standing with eyes closed (β = 0·23 and P= 0·001). No significant associations between protein 235 
intake and physical performance measures were observed among sarcopenic women, except for 236 
GS/BM change (β = 0·23 and P= 0·037) and a non-significant relation with chair rise change (β = 237 
0·27 and P= 0·064), which were lost after controlling for selected confounders and FM. 238 
The associations between total body FM and LM with physical performance measures and changes 239 
in them are shown in Table 5. After adjustment for LM and factors previously described as 240 
associated with physical performance, FM was negatively correlated with GS/BM, GS, knee 241 
extension/BM (only at the baseline), one leg stance, chair rises, WS 10m, squat, squat to the ground 242 
and SPPB score at the baseline and over 3-year follow-up (β ≥ -0·07 and P ≤ 0·050). FM was also 243 
negatively associated with change of standing with closed eyes 10 seconds (β = -0·22 and P < 244 
0·001). Further, LM was positively associated with GS, knee extension and one leg stance 245 
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performance at the baseline as well as with GS changes over 3- year  follow-up (β ≥ 0·06 and P ≤ 246 
0·025). Results remained significant after controlling for FM. 247 
Discussion 248 
This study examined cross-sectional and prospective associations of protein intake (g/kg BW) and 249 
body composition (FM and LM) with different PF and MS measures in 554 elderly women 250 
belonging to the OSTPRE-FPS study. Associations of protein intake with PF and MS were also 251 
evaluated according to sarcopenia status. However, the significant associations were lost in the final 252 
models due to high collinearity of FM with physical performance. Our findings supported the 253 
hypothesis that higher protein intake than the current RDA (0·8 g/ kg BW), might be associated 254 
with better PF and MS among elderly women. Further, present study showed that the total body FM 255 
was negatively associated with physical performance tests, while total body LM was positively 256 
associated with GS, knee extension and one leg stance. 257 
In recent years, there has been increased support for the contention that the current daily allowance 258 
(0∙8 g/kg BW) for protein is insufficient to promote optimal health and preserve physical 259 
performance in the elderly (5,12,13,18,45-47). Consistently, in our cross-sectional findings, those women 260 
with higher protein intake performed better in many of the physical performance measures as 261 
compared to those who had moderate and lower protein intakes. The higher protein intake category 262 
had greater GS/BM, knee extension/BM, longer one leg stance, better chair rises performance, 263 
faster WS 10 m, better squat and squat to the ground ability, and higher SPPB score. The 264 
prospective results showed also that women in higher protein intake group had less decline in 265 
GS/BM and one leg stance performance, and had the highest increased chair rises performance over 266 
3-year follow-up. No significant differences were observed between protein intake categories and 267 
WS 10 m and tandem walk speed 6 m prospectively. Thus, it might be that higher protein intake 268 
(g/kg BW) can be more related to preserving MS rather than mobility, which may partially explain 269 
the protein-frailty association. However, these associations were no longer significant after 270 
adjustment for FM. 271 
Findings of study by Gregorio et al.(13) among 387 healthy women aged 60 to 90 years, showed that 272 
those in the lower protein intake < 0·8 g/ kg BW category performed less well in the single leg 273 
stance test than those in the higher protein intake ≥ 0·8 g/ kg BW category. They also walked eight 274 
feet at a slower pace and their SPPB score was lower than in women in the higher protein category. 275 
Further, Lemieux et al.(45) indicated that among 72 postmenopausal women, higher protein intake ≥ 276 
1·2 g/kg BW was positively correlated to GS and knee extension. Women’s Health Initiative 277 
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clinical and observational study (12), was conducted in 134961 participants, aged 50 to 79 years for 278 
average 7 years of follow-up. Results showed that mean GS at baseline was slightly higher among 279 
women with higher calibrated daily protein intake (using urinary nitrogen protocol to estimate 280 
protein consumption over 24-h period), and these women experienced smaller decline in GS over 281 
time than those with low calibrated protein intake. Additionally, women in the highest quintile of 282 
calibrated protein intake completed on average 0·5 more chair rise at baseline than women in the 283 
lowest quintile. In contrast, there was no significant association between calibrated protein intake 284 
and the timed 6-meter walk in either cross-sectional or prospective analyses. Furthermore, the same 285 
results were shown when protein intake was expressed as g/kg BW. 286 
A new finding was that  among non-sarcopenic women at the baseline, protein intake (g/kg BW) 287 
was in positive relationship with GS/BM, knee extension/BM, one leg stance ability, chair rises 288 
performance, WS 10m, ability to squat and squat to the ground and SPPB. Protein intake in these 289 
women was also associated with preserving physical performance over 3 years follow-up, including 290 
one leg stance and standing with eyes closed 10s. No such an association was observed in 291 
sarcopenic women except a positive relationship between protein intake and GS change. Thus 292 
consistent to our hypothesis the positive association of protein intake (g/kg BW) with PF was more 293 
pronounced in non-sarcopenic than in sarcopenic women. It has been suggested that older 294 
individuals suffering from illness, physiological stress or sarcopenia are required to consume higher 295 
protein intake (1·2-1·5 g/ kg BW) as compared to healthy older people (1-1·2 g/ kg BW) (30). 296 
However, we could not explore this due to the threshold of protein intake in this data between 297 
sarcopenic and non-sarcopenic women. 298 
A preponderance of evidence now suggests that aging might result in the stimulation of MPS 299 
becoming resistance to the anabolic effect of hyperaminoacidemia, particularly at lower protein 300 
intakes (24,30,48-50). It was shown in study by Moore et al.(28) that the relative quantity of ingested 301 
protein required to maximize MPS is greater in older as compared with younger men (18) . However, 302 
it is unestablished whether elderly individuals with greater LM have higher capacity of MPS as 303 
compared to those with lower LM. Besides, previous research indicates that protein from different 304 
sources (animal and plant protein) may have different effects on physical performance (51,52). 305 
However, this study did not find any significant association between animal and plant protein intake 306 
with PF and MS measures. 307 
Declines in LM might predict a reduction in muscle force and performance (1,48). It has also been 308 
shown that FM is associated with functional decline and muscle weakness in elderly individuals 309 
(35,44,53). In this study, total body FM was in strong negative correlation with all PF and MS 310 
12 
measures at the baseline and changes in them at 3 years except for knee extension, tandem walk and 311 
standing with eyes closed at the baseline; while LM was positively correlated with GS and change 312 
in it, knee extension and one leg stance. Therefore, these findings accompanied with the loss of 313 
significant associations between protein intake and physical performance measures after controlling 314 
for FM but not LM, suggest that FM and LM may have opposite association with PF and MS in 315 
elderly women. There are different pathways through which fatness might be related to LM and 316 
muscle strength (54). However, more studies are needed to disentangle the relationship between FM 317 
and physical performance. 318 
It is well known that adequate energy intake is required to optimally utilize dietary protein to 319 
maintain physical performance rather than as energy source (13). It was to our surprise that those 320 
with higher energy and protein intake had a lower weight. The actual cause is uncertain but this 321 
might be due to higher physical activity level in higher protein category, and also possible 322 
underreporting of total energy and fat intake in those with higher BMI (55). Worthy of note is that 323 
LM index (LM/ height (m2)) and RSMI are both used as indicators of muscle mass in the diagnosis 324 
of sarcopenia (2). However, in this study protein intake showed the same association with LM index 325 
and RSMI, thus we used RSMI as clinical indicator of sarcopenia as adapted by EWGSOP (2). 326 
A limitation of this study was that the study population consists of only elderly women and 327 
therefore caution should be taken when generalizing the findings to elderly men. The 3-day food 328 
records method has been described as a suitable instrument for assessing energy and protein intake 329 
in elderly people (56,57). The latter study has also validated protein intake against urinary nitrogen 330 
studies in both community dwelling and institutionalized elderly people (57). However, a single 3-331 
day dietary record at the baseline might not be an appropriate method to capture long term effect of 332 
protein intake. Albeit we covered a wide selection for several known confounders that might 333 
influence physical performance, other factors such as health status, habitual physical activity level 334 
and/or dietary habits in participants in different protein intake categories might have affected the 335 
observed results. Lastly, based on the observational nature of our study we cannot establish a causal 336 
association. 337 
An additional analyses in the present data showed no significant effect of vitamin D (800 IU) and 338 
calcium supplementation (1000 mg) on MS and PF and longitudinal analysis were controlled for 339 
study group receiving those. The availability of multiple standardized physical performance 340 
measures at baseline as well as over a 3-year period added significant strength to our study. 341 
Dynamometric measures of GS as a physical marker of lower limb strength and knee extension for 342 
a variety of functional tasks, such as walking, chair rising and stair climbing, particularly are 343 
13 
predominate for the quantification of physical performance in older adults (36,58). The introduced 344 
protein intake categories in present study took into account the newer intake recommendations for 345 
elderly, which have not been used in the previous studies. 346 
Conclusion 347 
It is appropriate to focus on the relationship between protein intake, and MS and PF in the elderly 348 
because this group is most vulnerable to nutritional deficiencies. This cohort study suggests that 349 
higher protein intake and lower FM might be positively associated with MS and PF in elderly 350 
women. However, further research is required to establish causal association. 351 
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Table 1. Baseline characteristics of the participants in different protein intake categories (g/kg BW). 
 
≤ 0·8 g/kg body weight  
(n=171) 
0·81-1·19 g/kg body weight  
(n=269) 
≥ 1·2 g/kg body weight 
(n=112) 
P* 
Demographic  Mean SD Mean SD Mean SD  
Age (year) 68·0 a 1·9 67·8  b 1·9 67·7   1·8 0·003 
Weight (kg) 79·1  a 12·2 71·5 b 10·8 66·0 10·6 0.001 
Height (cm) 158·6 5·3 158·8  5·2 158·4 5·3 0∙202 
Body mass index (kg/m2) 29·9 a 4·4 27·1 b 3·9 25·3 3·4 0.001 
Osteoporosis (%) 10·5  9·4  6·1  0·088 
Diabetes (%) 2·9  2·5  3·6  0·560 
Depression (%) 5·3  1·9  2·9  0·211 
Rheumatoid arthritis (%) 8·2  4·4  4·7  0·217 
Fall in last 12 months (%) 22·8  21·6  21·4  0·942 
Hormone therapy use (%) 46·9  a  44·4  b  61·9  0·009 
Physical activity† 100·2 112·6 106·4 72·5 111·4 140·3 0·536 
Body composition        
Fat mass (kg) 34·2  a 8·4 28·1  b 8·0 24·4   7·3 0·001 
Lean mass (kg) 41·3  a 4·5 40·1  b 4·4 39·1   4·0 0·035 
Lean mass index (kg/m2) 16·4  a 1·7 15·9 b 1·4 15·6   1·2 0·037 
Relative skeletal muscle index (kg/m2) 6·5  a 0·7 6·7  b 0·6 6·6   0·5 0·036 
Fat mass to lean mass ratio 0·82 0·17 0·70 0·18 0·62 0·17 0·164 
Dietary factors        
Energy intake (kJ/d) 5388  a 1251 6699 b 1125 8008  933 0·001 
Crude protein (g/d) 51·4 a 10·3 65·0 b 10·2 83·4  14·1 0·001 
Protein (% of energy) 16·4 3·1 17·4 2·5 18·6 3·1 0·001 
Carbohydrate (g/d) 165·7 45·5 187·6 37·0 219·1 46·3 0·001 
Carbohydrate (% of energy) 50·6   a 5·9 48·8 5·5 48·0 5·7 0·036 
Fat (g/d) 43·6 14·5 53·9 15·1 63·1 18·2 0·203 
Fat (% of energy) 30·8 5·4 31·3 5·6 31·1 5·7 0·112 
*ANCOVA and chi-square tests were used to evaluate the differences between participants’ characteristics and dietary intake with protein 
intake categories as expressed per body weight according to different recommendations. 
†Includes walking, gardening, cycling, cross-country skiing, and other more strenuous activity, times/month × strenuousness. 
 a Means that lowest category was significantly different than middle and highest categories after Tukey’s post hoc test. 
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b Means that middle category was significantly different than highest category after Tukey’s post hoc test 
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Table 2. Baseline characteristics of the participants according to sarcopenia status. 
 Non-sarcopenic (n= 369) Sarcopenia (n= 127) 
P* 
Demographic Mean SD Mean SD 
Age (year) 67·7 1·8 67·9 1·9 0·007 
Weight (kg) 74·7 12·1 64·8 8·8 0∙001 
Height (cm) 158·6 5·2 158·7 5·5 0·117 
Body mass index (kg/m2) 28·3 4·1 24·7 3·1 0·001 
Osteoporosis (%) 7·2  10·3  0·143 
Diabetes (%) 4·2  0·7  0·021 
Depression (%) 2·6  5·7  0·190 
Rheumatoid arthritis (%) 5·6  5·7  0·997 
Fall in last 12 months (%) 20·7  23·8  0·560 
Hormone therapy use (%) 49·0  53·9  0·581 
Physical activity† 108·5 112·3 104·6 85·3 0·472 
Body composition      
Fat mass (kg) 30·0 8·8 25·2 7·1 0·001 
Lean mass (kg) 41·4 4·1 36·4 2·5 0·001 
Lean mass index (kg/m2) 16·4 1·3 14·4 0·7 0·001 
Relative skeletal muscle index (kg/m2) 7·0 0·5 5·9 0·2 0·001 
Fat mass to lean mass ratio 0·72 0·19 0·69 0·18 0·004 
Dietary factors      
Energy intake (kJ/d) 6539 1518 6614 1564 0·001 
Protein (g/kg body weight) 0·94 0·28 1·04 0·30 0·021 
Protein (% of energy) 17·9 3·1 17·6 2·9 0·020 
Carbohydrate (g/d) 192·3 47·8 197·2 48·7 0·002 
Carbohydrate (% of energy) 48·8 5·7 49·5 6·1 0·006 
Fat (g/d) 53·6 17·6 55·0 19·6 0·001 
Fat (% of energy) 30·8 5·5 31·8 5·6 0·002 
*Independent sample t-test and chi-square tests were used to evaluate the differences between participant’s characteristics according to 
sarcopenia status. 
†Includes walking, gardening, cycling, cross-country skiing, and other more strenuous activity, times/month × strenuousness. 
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Table 3. Physical performance measures in protein intake categories at the baseline and over 3-year follow-up. 
Physical performance measures 
≤ 0·8 g/kg BW 
(n=171) 
 
0·81-1·19 g/kg BW 
(n=269) 
 
≥ 1·2 g/kg BW 
(n=112) 
 
P trend - value 
Mean SD Mean  SD Mean  SD Model 
1* 
Model 
2 ‡ 
Model 
3† 
Hand grip strength/body mass 
(kPa/kg) 
         
Baseline 0·32 a 0·08 0·37  b 0·06 0·40 0·01 < 0·001 0·001 0·342 
Change§ -1·51 a 6·70 -0·79 b 3·68 -0·68 3·42 0·020 0·027 0·779 
Hand grip strength (kPa)           
Baseline 25·96 a 7·04 26·23 b 4·88 24·53 4·56 0·029 0·657 0·135 
Change -1·51 6·70 -0·79 3·68 -0·68  3·43 0·538 0·358 0·967 
Knee extension/body mass (kPa/kg)          
Baseline 3·71 a 1·13 4·34 b 1·25 4·47 1·32 0·080 0∙003  0·799 
Knee extension (kPa)          
Baseline 282·07 81·73 307·01 85·70 285·99 77·19 0·104 0·822 0·240 
One leg stance 30 s          
Baseline 15·79 a 10·90 19·31 b 10·28 21·54 9·42 < 0·001 0·047 0·804 
Change -1·64 a 10·02 -1·50  b 10·89 -0·96 10·48 0·007 0·024 0·993 
Chair rises          
Baseline 7·87 a 6·97 7·84 b 2·86 8·41 2·20 0·042 0·043 0·720 
Change 0·12 a 6·07 0·83 b 2·82 1·15 2·68 0·001 0·725 0·111 
Tandem walk  speed 6 m (m/s)          
Baseline 0·30   0·09 0·34    0·37 0·33 0·12 0·675 0·959 0·254 
Change 0·02 0·11 -0·15 0·42 0·03 0·11 0·992 0·024 0·483 
Walking speed 10 m (m/s)          
Baseline 1·53 a 0·31 1·67 b 0·32 1·72 0·28 < 0·001 0·005 0·668 
Change -0·11 0·24 -0·10 0·33 -0·11 0·29 0·505 0·486 0·712 
Standing with eyes closed 10 s (%)          
Baseline 94∙1  a  95∙6  b  97∙0  0·050 0·381 0·412 
Change -5·54  -5·19  -4·94  0·646 0·873 0·100 
Ability to squat (%)          
Baseline 91·1 a  94·3 b  97·0  0·027 0·019 0·191 
25 
  
Change -0·08 a  0·32 b  0·21  0·012 0·100 0·503 
Ability to squat to the ground (%)          
Baseline 58·0  a   69·8  b  78·7  < 0·001 0·001 0·080 
Change -0·02  -0·01  -0·06  0·202 0·309 0·690 
Short physical performance 
battery score 
         
Baseline 5·52  a 1·82 6·28  b 1·87 6·51 1·77 < 0·001 0·004 0·586 
Change 1·35 0·21 1·55 0·14 1·57 0·24 0·968 0·908 0·845 
BW, Body weight. 
* Model 1 was adjusted for age and total energy intake. 
† Model 2 was adjusted for variables in model 1 plus smoking status, alcohol consumption (portions/week), physical activity level, 
hormone therapy use, osteoporosis, baseline height and lean mass. 
‡ Model 3 was adjusted for variables in model 2 but lean mass was replaced by fat mass. 
§ Longitudinal analyses were adjusted also for physical performance baseline variables and calcium and vitamin D intervention. 
Tests for a linear trend across categories of protein intake were conducted by using the median value in each category as a continuous 
variable in the linear and logistic regression models. Median total protein intake for each category was 0·66, 0·9·8 and 1·34 g/ kg BW, 
respectively. 
a Means that lowest category was significantly different than middle and highest categories after Tukey’s post hoc test. 
b Means that middle category was significantly different than highest category after Tukey’s post hoc test. 
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Table 4· Effect of protein intake (g/kg body weight) and physical performance measures according to sarcopenia status. 
Physical performance measures 
Non-sarcopenic (n=369) Sarcopenic (n=127) 
regression 
coefficient (95% CI) 
P 
Model 
1* 
P 
Model 
2‡ 
P 
Model 
3† 
regression 
coefficient (95% CI) 
P 
Model 
1* 
P 
Model 
2‡ 
P 
Model 
3† 
Hand grip strength/body mass 
(kPa/kg) 
        
Baseline 0·35 (0·07, 0·15) <0·001 <0·001 0·284 0·22 (0·04, 0·21) 0·041 0·320 0·806 
Change§ 0·09 (-0·48, 3·4) 0·138 0·237 0·666 0·20 (0·93, 11·06) 0·021 0·037 0·872 
Hand grip strength (kPa)         
Baseline -0·13 (-4·22, 0·17) 0·069 0·520 0·113  -0·23 (-4·22, 0·17) 0·114 0·850 0·334 
Change 0·18 (-1·49, 1·94) 0·018 0·430 0·406 0·06 (-3·14, 5·07) 0·043 0·257 0·690 
Knee extension/body mass 
(kPa/kg) 
        
Baseline 0·25 (0·72, 2·12) <0·001 0·008 0·726 0·28 (0·28, 2·50) 0·014 0·053 0·533 
Knee extension (kPa)         
Baseline -0·04 (-6·17, 17·03) 0·613 0·683 0·562 -0·07 (-4·81, 70·81) 0·642 0·552 0·562 
One leg stance 30 s         
Baseline 0·26 (5·62, 15·17) <0·001 0·001 0·974 0·45 (-2·40, 14·20) 0·762 0·545 0·948 
Change 0·14 (0·44, 9·60) 0·032 0·037 0·658 -0·48 (-10·0, 5·64) 0·718 0·489 0·055 
Chair rises         
Baseline 0·15 (0·65, 4·13) 0·038 0·039 0·658 0·01 (-8·15, 1·82) 0·987 0·235 0·486 
Change 0·20 (1·02, 3·59) <0·001 0·182 0·653 0·27 (0·02, 5·22) 0·064 0·126 0·228 
Tandem walk  speed 6 m (m/s)         
Baseline 0·31 (-0·05, 0·09) 0·687 0·560 0·989 -0·23 (-0·62, 0·20) 0·133 0·667 0·972 
Change 0·02 (-0·05, 0·06) 0·682 0·692 0·793 -0·13 (-0·04, 0·11) 0·616 0·844 0·728 
Walking speed 10 m (m/s)         
Baseline 0·30 (0·17, 0·48) <0·001 <0·001 0·161 0·11 (-0·11, 0·36) 0·769 0·267 0·429 
Change 0·23 (-0·02, 0·24) 0·119 0·854 0·324 -0·01 (-0·28, 0·24) 0·784 0·608 0·978 
Standing with eyes closed 10 s 
(%) 
        
Baseline 0·04 (-0·06, 0,13) 0·514 0·305 0·850 -0·11 (-0·14, 0·05) 0·383 0·564 0·650 
Change 0·23 (0·62, 2·37) 0·001 0·001 0·096 0·13 (-0·47, 1·54) 0·297 0·246 0·557 
Ability to squat (%)         
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Baseline 0·18 (0·04, 0·25) 0·006 0·003 0·964 0·08 (-0·05, 0·09) 0·536 0·309 0·545 
Change 0·09 (-0·03, 0·26) 0·134 0·190 0·528 0·15 (-0·10, 0·40) 0·256 0·123 0·578 
Ability to squat to the ground 
(%) 
        
Baseline 0·29 (0·26, 0·68) 0·001 0·001 0·852 0·10 (-0·22, 0·52) 0·432 0·652 0·333 
Change 0·59 (-0·11, 0·33) 0·340 0·389 0·224 0·04 (-0·30, 0·45) 0·682 0·381 0·677 
Short physical performance 
battery score 
        
Baseline 0·32 (1·15, 2·86) <0·001 <0·001 0·177 -0·05 (-1·89, 1·23) 0·722 0·214 0·132 
Change 0·15 (0·09, 2·11) 0·032 0·301 0·919 -0·02 (-1·80, 1·59) 0·880 0·876 0·983 
 *Model 1 was adjusted for age and total energy intake. 
† Model 2 was adjusted for variables in model 1 plus smoking status, alcohol consumption (portions/week), physical activity level, 
hormone therapy use, osteoporosis, study group and baseline height. 
‡Model 3 was adjusted for variables in model 2 plus fat mass. 
§ Longitudinal analyses were adjusted also for physical performance baseline variables and calcium and vitamin D intervention. 
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Table 5. Association of total body fat mass and lean mass with physical performance measures at the baseline and over 3-year follow-
up. 
Physical performance measures 
Total body fat mass Total body lean mass 
β SE 
P 
Model 1* 
P 
Model 2† 
β SE 
P 
Model 1 
P 
Model 2 
Hand grip strength/body mass (kPa/kg)         
Baseline -0∙58 0∙01 <0∙001 <0∙001 -0∙01 0∙01 <0∙001 0∙821 
Change § -0∙33 0∙01 <0∙001 <0∙001 0∙04 0∙01 0∙079 0∙429 
Hand grip strength (kPa)          
Baseline -0∙10 0.03 0∙754 0∙029 0∙21 0∙01 <0∙001 <0∙001 
Change -0∙09 0.02 0∙622 0∙050 0∙11 0∙01 0∙014 0∙002 
Knee extension/body mass (kPa/kg)         
Baseline -0∙47 0∙01 <0∙001 <0∙001 0∙09 0∙01 0∙003 0∙079 
Knee extension (kPa)         
Baseline 0∙02 0∙46 0∙570 0∙094 0∙26 0∙01 0∙002 <0∙001 
One leg stance 30 s         
Baseline -0∙28 0∙05 <0∙001 <0∙001 0∙06 0∙01 <0∙001 0∙025 
Change -0.19 0∙05 <0∙001 <0∙001 0∙17 0∙11 <0∙001 0∙119 
Chair rises         
Baseline -0∙14 0∙02 0∙004 0∙005 0∙03 0∙01 0∙398 0∙537 
Change -0∙16 0∙01 <0∙001 <0∙001 0∙09 0∙03 0∙012 0∙822 
Tandem walk  speed 6 m (m/s)         
Baseline 0∙07 0∙02 0∙337 0∙177 -0∙03 0∙04 0∙580 0.266 
Change -0∙01 0∙01 0∙666 0∙865 -0∙01 0∙02 0∙536 0∙638 
Walking speed 10 m (m/s)         
Baseline -0∙34 0∙02 <0∙001 <0∙001 0∙03 0∙04 <0∙001 0∙502 
Change -0∙13 0∙02 0∙003 0∙017 -0∙01 0∙04 0∙060 0∙546 
Standing with eyes closed 10 s (%)         
Baseline -0∙05 0∙01 0∙034 0∙256 -0∙09 0∙03 0∙017 0∙118 
Change -0∙22 0∙02 <0∙001 <0∙001 -0∙01 0∙02 0∙031 0∙991 
Ability to squat (%)         
Baseline -0∙23 0∙01 <0∙001 <0∙001 0∙02 0∙03 0∙005 0∙721 
Change -0∙16 0∙02 <0∙001 0∙001 0∙18 0∙04 0∙177 0∙738 
Ability to squat to the ground (%)         
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Baseline -0∙33 0∙03 <0∙001 <0∙001 0∙01 0∙06 <0∙001 0∙185 
Change -0∙07 0∙01 <0∙001 <0∙001 0.07 0∙06 0∙732 0∙657 
Short physical performance battery score         
Baseline -0∙32 0∙01 <0∙001 <0∙001 0∙01 0∙02 <0∙001 0∙738 
Change -0∙27 0∙01 <0∙001 <0∙001 0∙06 0∙02 0∙001 0∙252 
SPPB, short physical performance battery. 
*Model 1 was adjusted for age, total energy intake, smoking status, alcohol consumption (portions/week), physical activity level, 
hormone therapy use, osteoporosis and height. 
† Model 2 adjusted for variables in model 1, and lean mass and fat mass were adjusted for each other.  
§ Longitudinal analyses were adjusted also for physical performance baseline variables and calcium and vitamin D intervention. 
